Objective The aim of this study was to assess the efficacy and safety of adalimumab (ADA), a recombinant human monoclonal antibody against tumour necrosis factor a (TNF), for the induction of clinical remission in anti-TNF naı̈ve patients with moderately to severely active ulcerative colitis. Methods This 8-week, multicentre, randomised, doubleblind, placebo-controlled study (NCT00385736), conducted at 94 centres in North America and Europe, enrolled ambulatory adult patients with Mayo score of $6 points and endoscopic subscore of $2 points despite treatment with corticosteroids and/or immunosuppressants. Under the original study protocol, 186 patients were randomised (1:1) to subcutaneous treatment with ADA160/80 (160 mg at week 0, 80 mg at week 2, 40 mg at weeks 4 and 6) or placebo. Subsequently, at the request of European regulatory authorities, the protocol was amended to include a second induction group (ADA80/40: 80 mg at week 0, 40 mg at weeks 2, 4 and 6). The primary efficacy endpoint was clinical remission (Mayo score #2 with no individual subscore >1) at week 8, assessed in 390 patients randomised (1:1:1) to ADA160/80, ADA80/40, or placebo. Safety was assessed in all enrolled patients. Patients, study site personnel, investigators, and the sponsor were blinded to treatment assignment. Results At week 8, 18.5% of patients in the ADA160/80 group (p1⁄40.031 vs placebo) and 10.0% in the ADA80/40 group (p1⁄40.833 vs placebo) were in remission, compared with 9.2% in the placebo group. Serious adverse events occurred in 7.6%, 3.8% and 4.0% of patients in the placebo, ADA80/40, and ADA160/80 groups, respectively. There were two malignancies in the placebo group, none in the ADA groups. There were no cases of tuberculosis and no deaths. Conclusions ADA160/80 was safe and effective for induction of clinical remission in patients with moderately to severely active ulcerative colitis failing treatment with corticosteroids and/or immunosuppressants. Clinical trial NCT00385736. INTRODUCTION Ulcerative colitis is an idiopathic, chronic inflammatory disease of the large intestine, usually involving the rectum, characterised by a continuous pattern of inflammation and ulceration of the intestinal mucosa and submucosa. Ulcerative colitis has a significant negative impact on patient quality of life and places a substantial financial burden on healthcare systems, with direct cost estimates exceeding $3.4 billion in the USA and €5.4 billion in Europe. The goal of therapy in ulcerative colitis is to induce and maintain remission. Conventional medical therapies include 5-aminosalicylic acid, corticosteroids and oral immunosuppressants (azathioprine, 6-mercaptopurine and cyclosporine). However, these agents inadequately control the disease in a substantial proportion of patients and can lead to adverse events (AEs). Thus, there is a need for new therapies beyond conventional treatment options for many patients with ulcerative colitis. See Commentary, p 741 < Additional materials are published online only. To view these files please visit the journal online (http://gut.bmj.com). Medical University Vienna, Vienna, Austria Mayo Clinic, Rochester, Minnesota, USA Leiden University Medical Center, Leiden, Netherlands Academic Medical Centre, Amsterdam, Netherlands University of Chicago Medical Center, Chicago, Illinois, USA Christian-Albrechts-University, University-Hospital Schleswig-Holstein, Medical Department I, Kiel, Germany University of Calgary, Calgary, AB, Canada University of Alberta, Edmonton, AB, Canada Abbott, Abbott Park, Illinois, USA Abbott, Maidenhead, UK Abbott, Ludwigshafen, Germany Correspondence to Dr Walter Reinisch, Universitätsklinik für Innere Medizin III, Abteilung Gastroenterologie and Hepatologie, Waehringer Guertel 18-20, A-1090 Vienna, Austria; walter.reinisch@ meduniwien.ac.at Revised 3 November 2010 Accepted 15 November 2010 Published Online First 5 January 2011 Significance of this study What is already known about this subject? < Conventional treatments for moderate to severely active ulcerative colitis have limited efficacy and are associated with adverse events. < One biological therapy, the anti-TNFa chimeric monoclonal antibody infliximab, has been proven to induce and maintain remission in ulcerative colitis patients. < Adalimumab (ADA), a fully human monoclonal antibody against TNFa, is effective in inducing and maintaining remission in moderately to severely active Crohn’s disease, but its efficacy in ulcerative colitis is unknown. What are the new findings? < This trial demonstrated that ADA is effective in inducing remission in moderately to severely active ulcerative colitis. < At week 8, 18.5% of patients in the ADA160/80 group (p1⁄40.031 vs placebo) and 10.0% in the ADA80/40 group (p1⁄40.833 vs placebo) were in remission, compared with 9.2% in the placebo group. < Adalimumab was well tolerated, with a safety profile comparable to those seen in clinical trials. How might it impact on clinical practice in the foreseeable future? < Follow-up of the patients in this trial is ongoing. 780 Gut 2011;60:780e787. doi:10.1136/gut.2010.221127 Inflammatory bowel disease group.bmj.com on April 9, 2013 Published by gut.bmj.com Downloaded from
[1]
J. Chao,et al.
Systematic review: the costs of ulcerative colitis in Western countries
,
2010,
Alimentary pharmacology & therapeutics.
[2]
S. Targan,et al.
Prospective randomized open‐label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid‐refractory ulcerative colitis†
,
2010,
Inflammatory bowel diseases.
[3]
T. Kaptchuk,et al.
Biological, clinical, and ethical advances of placebo effects
,
2010,
The Lancet.
[4]
M. Dubinsky,et al.
The Impact of Ulcerative Colitis on Patients’ Lives Compared to Other Chronic Diseases: A Patient Survey
,
2010,
Digestive Diseases and Sciences.
[5]
D. Rubin,et al.
Open‐label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab
,
2009,
Inflammatory bowel diseases.
[6]
J. E. Domínguez-Muñoz,et al.
Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years.
,
2009,
World journal of gastroenterology.
[7]
B. Dijkmans,et al.
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
,
2009,
Annals of the rheumatic diseases.
[8]
G. D'Haens,et al.
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial
,
2008
.
[9]
E. Levitan,et al.
Meta-Analysis of the Placebo Response in Ulcerative Colitis
,
2008,
Digestive Diseases and Sciences.
[10]
L. Peyrin-Biroulet,et al.
Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study.
,
2007,
World journal of gastroenterology.
[11]
P. Rutgeerts,et al.
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
,
2007,
Gastroenterology.
[12]
S. Targan,et al.
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial
,
2006,
Gut.
[13]
A. Moss,et al.
Infliximab for induction and maintenance therapy for ulcerative colitis.
,
2006,
Gastroenterology.
[14]
P. Rutgeerts,et al.
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
,
2006,
Gastroenterology.
[15]
G. Lichtenstein.
Treatment of Ulcerative Colitis With a Humanized Antibody to the α4β7 Integrin
,
2006
.
[16]
Å. Danielsson,et al.
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.
,
2005,
Gastroenterology.
[17]
M. Cheang,et al.
Quantification of the placebo response in ulcerative colitis.
,
1997,
Gastroenterology.
[18]
S. Targan,et al.
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
,
1997,
The New England journal of medicine.
[19]
R. Sartor,et al.
Cytokines in intestinal inflammation: pathophysiological and clinical considerations.
,
1994,
Gastroenterology.
[20]
T. Macdonald,et al.
Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.
,
1993,
Gut.
[21]
S. Stephens,et al.
Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
,
1992,
The Lancet.
[22]
M. Savage,et al.
Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.
,
1991,
Gut.
[23]
W. Tremaine,et al.
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
,
1987,
The New England journal of medicine.